Immuneering
IMRX
34 hedge funds and large institutions have $115M invested in Immuneering in 2023 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 13 increasing their positions, 12 reducing their positions, and 6 closing their positions.
102% more capital invested
Capital invested by funds: $56.9M → $115M (+$58M)
8% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 12
0.33% more ownership
Funds ownership: 44.39% → 44.72% (+0.33%)
0% more funds holding
Funds holding: 34 → 34 (0)
0% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$1.42M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$738K |
| 3 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$568K |
| 4 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$545K |
| 5 |
ECM
ExodusPoint Capital Management
New York
|
+$490K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$2.22M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$915K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$209K |
| 4 |
AFM
Anson Funds Management
Dallas,
Texas
|
-$158K |
| 5 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$113K |
IMRX Hedge Fund Activity: Q1 2023 in Review
34 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Immuneering (IMRX) for Q1 2023, worth a combined $115M — up 102% from $56.9M a quarter earlier.
Fund positioning in IMRX was balanced in Q1 2023: 6 funds opened new positions, 6 closed out, 13 added to existing stakes and 12 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $1.42M. The largest seller was T. Rowe Price Investment Management, exiting entirely with an estimated $2.22M sold.
- 34 institutional investors held Immuneering (IMRX) as of Q1 2023, unchanged from Q4 2022.
- Funds reported $115M of Immuneering stock for Q1 2023, up 102% quarter-over-quarter.
- 6 funds opened new Immuneering positions in Q1 2023 and 6 closed out, a net change of 0 holders.
- The largest Immuneering buyer in Q1 2023 was Fidelity Investments, an estimated $1.42M added.
- The largest Immuneering seller in Q1 2023 was T. Rowe Price Investment Management, an estimated $2.22M sold.
Based on aggregated 13F filings for Q1 2023.